Barclays Reaffirms “Overweight” Rating for Eli Lilly And Co (LLY)
Eli Lilly And Co (NYSE:LLY)‘s stock had its “overweight” rating reaffirmed by equities researchers at Barclays in a note issued to investors on Tuesday, The Fly reports. They currently have a $112.00 target price on the stock. Barclays’ target price would indicate a potential upside of 5.95% from the company’s previous close.
Several other equities research analysts have also recently weighed in on the company. Cantor Fitzgerald set a $110.00 price target on Eli Lilly And Co and gave the company a “buy” rating in a research report on Monday. TheStreet cut Eli Lilly And Co from a “b” rating to a “c+” rating in a research report on Friday, August 24th. ValuEngine upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Morgan Stanley upped their price target on Eli Lilly And Co from $93.00 to $102.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 31st. Finally, SunTrust Banks reiterated a “buy” rating and set a $105.00 price target on shares of Eli Lilly And Co in a research report on Tuesday, July 31st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $101.00.
NYSE LLY opened at $105.71 on Tuesday. The stock has a market cap of $113.60 billion, a price-to-earnings ratio of 24.70, a price-to-earnings-growth ratio of 1.76 and a beta of 0.27. Eli Lilly And Co has a 52 week low of $73.69 and a 52 week high of $107.84. The company has a current ratio of 1.40, a quick ratio of 1.09 and a debt-to-equity ratio of 0.79.
In related news, insider Donald A. Zakrowski sold 600 shares of the company’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $105.57, for a total value of $63,342.00. Following the transaction, the insider now directly owns 3,530 shares in the company, valued at $372,662.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 185,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 24th. The stock was sold at an average price of $92.03, for a total transaction of $17,025,550.00. Following the completion of the transaction, the insider now owns 121,631,601 shares in the company, valued at $11,193,756,240.03. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,685,070 shares of company stock worth $167,108,944. 0.11% of the stock is owned by company insiders.
Hedge funds have recently bought and sold shares of the stock. Integrated Wealth Concepts LLC bought a new position in shares of Eli Lilly And Co in the second quarter worth approximately $103,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of Eli Lilly And Co in the second quarter worth approximately $114,000. Legacy Advisors LLC increased its position in shares of Eli Lilly And Co by 118.0% in the second quarter. Legacy Advisors LLC now owns 1,354 shares of the company’s stock worth $116,000 after purchasing an additional 733 shares during the last quarter. Fort L.P. bought a new position in shares of Eli Lilly And Co in the second quarter worth approximately $121,000. Finally, Financial Management Professionals Inc. bought a new position in shares of Eli Lilly And Co in the second quarter worth approximately $128,000. Institutional investors own 76.52% of the company’s stock.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Story: What kind of dividend yield to CEF’s pay?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.